The Combination of Grazoprevir, a Hepatitis C Virus (HCV) NS3/4A Protease Inhibitor, and Elbasvir, an HCV NS5A Inhibitor, Demonstrates a High Genetic Barrier to Resistance in HCV Genotype 1a Replicons

The selection of resistance-associated variants (RAVs) against single agents administered to patients chronically infected with hepatitis C virus (HCV) necessitates that direct-acting antiviral agents (DAAs) targeting multiple viral proteins be developed to overcome failure resulting from emergence...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Antimicrob Agents Chemother
Main Authors: Lahser, Frederick C., Bystol, Karin, Curry, Stephanie, McMonagle, Patricia, Xia, Ellen, Ingravallo, Paul, Chase, Robert, Liu, Rong, Black, Todd, Hazuda, Daria, Howe, Anita Y. M., Asante-Appiah, Ernest
Formato: Artigo
Idioma:Inglês
Publicado em: American Society for Microbiology 2016
Assuntos:
Antiviral Agents
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4862497/
https://ncbi.nlm.nih.gov/pubmed/26926625
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.00051-16
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados